Evidence map›Paper›PMID 31184423›Full record

ArticleJournal of cellular and molecular medicine2019

Sublytic C5b-9 induces proliferation of glomerular mesangial cells via ERK5/MZF1/RGC-32 axis activated by FBXO28-TRAF6 complex.

Tianyi Yu, Lulu Wang, Chenhui Zhao, Baomei Qian, Chunlei Yao, Fengxia He, Yufeng Zhu, Mengyuan Cai, Mei Li, Dan Zhao and 3 more

Open access · goldAbstract read
In one paragraph

Article in Journal of cellular and molecular medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Tianyi YuDepartment of Immunology, Nanjing Medical University, Nanjing, People's Republic of China.
Lulu WangDepartment of Immunology, Nanjing Medical University, Nanjing, People's Republic of China.
Chenhui ZhaoDepartment of Medicine, First Affiliated Hospital of Nanjing Medical University, Nanjing, People's Republic of China.
Baomei QianDepartment of Immunology, Nanjing Medical University, Nanjing, People's Republic of China.
Chunlei YaoDepartment of Medicine, First Affiliated Hospital of Nanjing Medical University, Nanjing, People's Republic of China.
Fengxia HeDepartment of Immunology, Nanjing Medical University, Nanjing, People's Republic of China.
Yufeng ZhuClinical Medical Science of the First Clinical Medical College, Nanjing Medical University, Nanjing, People's Republic of China.
Mengyuan CaiClinical Medical Science of the First Clinical Medical College, Nanjing Medical University, Nanjing, People's Republic of China.
Mei LiThe Laboratory Center for Basic Medical Sciences, Nanjing medical University, Nanjing, People's Republic of China.
Dan ZhaoDepartment of Immunology, Nanjing Medical University, Nanjing, People's Republic of China.
Jing ZhangDepartment of Immunology, Nanjing Medical University, Nanjing, People's Republic of China.
Yingwei WangDepartment of Immunology, Nanjing Medical University, Nanjing, People's Republic of China.
Wen QiuDepartment of Immunology, Nanjing Medical University, Nanjing, People's Republic of China.ORCID 0000-0003-2097-9773
Nanjing Medical University · CNJiangsu Province Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mesangioproliferative glomerulonephritis (MsPGN) is characterized by the proliferation of glomerular mesangial cells (GMCs) and accumulation of extracellular matrix (ECM), followed by glomerulosclerosis and renal failure of patients. Although our previous studies have demonstrated that sublytic C5b-9 complex formed on the GMC membrane could trigger GMC proliferation and ECM expansion of rat Thy-1 nephritis (Thy-1N) as an animal model of MsPGN, their mechanisms are still not fully elucidated. In the present studies, we found that the levels of response gene to complement 32 (RGC-32), myeloid zinc finger 1 (MZF1), phosphorylated extracellular signal-regulated kinase 5 (phosphorylated ERK5, p-ERK5), F-box only protein 28 (FBXO28) and TNF receptor-associated factor 6 (TRAF6) were all markedly up-regulated both in the renal tissues of rats with Thy-1N (in vivo) and in the GMCs upon sublytic C5b-9 stimulation (in vitro). Further in vitro experiments revealed that up-regulated FBXO28 and TRAF6 could form protein complex binding to ERK5 and enhance ERK5 K63-ubiquitination and subsequent phosphorylation. Subsequently, ERK5 activation contributed to MZF1 expression and MZF1-dependent RGC-32 up-regulation, finally resulting in GMC proliferative response. Furthermore, the MZF1-binding element within RGC-32 promoter and the functions of FBXO28 domains were identified. Additionally, knockdown of renal FBXO28, TRAF6, ERK5, MZF1 and RGC-32 genes respectively markedly reduced GMC proliferation and ECM production in Thy-1N rats. Together, these findings indicate that sublytic C5b-9 induces GMC proliferative changes in rat Thy-1N through ERK5/MZF1/RGC-32 axis activated by the FBXO28-TRAF6 complex, which might provide a new insight into MsPGN pathogenesis.

Indexed as

AnimalsCell Cycle ProteinsCell ProliferationComplement Membrane Attack ComplexExtracellular MatrixLysineMaleMesangial CellsMitogen-Activated Protein Kinase 7Muscle ProteinsNerve Tissue ProteinsPromoter Regions, GeneticRats, Sprague-DawleySignal TransductionSKP Cullin F-Box Protein LigasesThy-1 AntigensCell Cycle ProteinsComplement Membrane Attack ComplexLysineMitogen-Activated Protein Kinase 7Muscle ProteinsMZF1 protein, ratNerve Tissue ProteinsRgcc protein, ratSKP Cullin F-Box Protein LigasesThy-1 AntigensTNF Receptor-Associated Factor 6Trans-Activatorsextracellular matrixFBXO28-TRAF6 complexglomerular mesangial cellsproliferationsublytic C5b-9ubiquitination

Identifiers

PMID31184423
PMCPMC6653533
OpenAlexW2994367416

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.